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Background: We offer some perspectives and commentary on the sedation of obese patients in the intensive care
unit (ICU).
Discussion: Sedation in morbidly obese patients should conform to the same broad principles now current in ICU
practice. These include a general presumption against benzodiazepines as first-line agents. Opioids should be avoided
in any situation where spontaneous breathing is required. Remifentanil is the preferred agent where continuous stable
opioid levels using an infusion are required, because of its lack of context-sensitive accumulation. Volatile anaesthetics
may be an option for the same reason but there are no substantial, controlled demonstrations of effectiveness/safety in
short-term use in the ICU setting. Propofol is a valuable resource in the morbidly obese patients but the duration of
continuous sedation should not exceed 6 days, in order to avoid propofol infusion syndrome. Alpha-2 agonists offer a
range of theoretically positive features for the sedation of morbidly obese patients, but at present there is a lack of
pharmacokinetic data and a critical mass of high-grade clinical data. Dexmedetomidine has the attraction of not
causing respiratory depression or obstructive breathing during sedation and its sympatholytic effects should help
deliver stable blood pressure and heart rate. Ketamine has a poor tolerability profile in adults so its use in the ICU
context is largely confined to paediatrics.
Conclusion: None of the agents currently available is ideal for every situation encountered in the management of
morbidly obese patients. This article identifies additional research needed to place sedation practice of obese
patients on a more systematic footing.
Keywords: Clonidine, Dexmedetomidine, Intensive care, Ketamine, Obesity, Opioids, Propofol, Sedation, Volatile
anaesthetics, BenzodiazepinesReview
Background
Nowadays obesity is undoubtedly more prevalent than in
earlier times [1,2]. This change has filtered through the
intensive care medicine, with the result that greater
numbers of obese patients are encountered in critical
care.
It is important to keep a sense of proportion about this
trend. Firstly, it is our view that significant obesity-
related challenges to the clinical management of critic-
ally ill patients emerge consistently only when body* Correspondence: riku.aantaa@tyks.fi
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unless otherwise stated.mass index (BMI) equals or exceeds 35 kg/m2. The pro-
portion of critically ill patients meeting that condition is
still relatively small (≈10%) [3]. Therefore, we consider it
unhelpful to promote the idea that intensive care units
(ICUs) throughout Europe are being tested beyond their
capacities by large numbers of morbidly obese patients:
this is not the case.
Moreover, many of the problems presented by mor-
bidly obese patients in the perioperative period are well
appreciated and the principles of good practice/risk re-
duction are established. These include a preference for
the beach-chair position (and certainly the avoidance of
supine positioning for intubation [4]), protocols and
equipment specifications for difficult airway manage-
ment [5], lung-protective ventilation [2] and the use ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pressure (PEEP) [6]. Practical issues of staffing and the
provision of suitable equipment (e.g. hoists and beds
with suitable load-bearing capacity) must be acknowl-
edged but not overstated, even though some of the solu-
tions involve obvious economic costs.
Nevertheless, there are distinct clinical challenges in
the management of morbidly obese patients. Notable
among these are deleterious effects of obesity on the re-
spiratory system, where the following difficulties may be
encountered [7].
• Impaired function of respiratory muscles,
diminished functional residual capacity and
limitation of expiratory flow [8,9].
• Increased oxygen consumption, increased
production of carbon dioxide and increased work of
breathing [10].
• Increased upper airway resistance and propensity to
obstructive sleep apnoea syndrome (OSAS) [8,11].
• Potential for obesity–hypoventilation syndrome,
followed by pulmonary hypertension and right heart
failure [12,13].
As a first step in any discussion about the challenges
of managing the morbidly obese ICU patient it is im-
portant to appreciate that obesity is not merely a ques-
tion of mass: qualitative factors of obesity have also to
be considered. First, central or visceral obesity-more
often encountered in men-appears to be a more malign
form than peripheral obesity. Moreover, not all of the
excess weight of morbidly obese patients is fat: lean body
mass is also increased but usually not in proportion to
adipose tissue. The fat:lean ratio is thus often different
in obese patients than in otherwise comparable persons
of normal weight. Distinctions between total body
weight, lean body weight and ideal body weight are rele-
vant to ventilator settings and drug dosage [14]. For ex-
ample, the tidal volume calculated from the BMI will
likely be far too large; correct (i.e. smaller) volumes need
to be derived from the ideal body weight. Shifts in vol-
umes of drug distribution in adipose tissue and body
water, alterations in tissue/blood partition coefficients
and clearance rates, changes in the affinity of drugs for
plasma proteins and/or tissue components, increase in
metabolization and altered regional/adipose blood flow
may all be encountered in obese patients and affect the
pharmacokinetic/pharmacodynamic profiles of sedative
and anaesthetic drugs [15-17].Commentary
Use of sedatives in morbidly obese patients can be con-
sidered under several therapeutic categories/situations:• non-invasive ventilation
• intubated ventilation
• short-term sedation (<24 h)
• long-term sedation (≥24 h).
There is overlap between several of these categories so
that, for example, long-term sedation may be more likely
in a setting of invasive mechanical ventilation.
Sedatives used in the management of morbidly obese
patients
We believe that sedation in morbidly obese patients should
conform to the same broad principles now current in ICU
practice. These include:
• maintaining the patient in a state of calm, awake
cooperation
• multimodal sedation
• a strong presumption against first-line use of benzo-
diazepines and long-acting opioids.
Table 1 summarizes our views on the profiles of differ-
ent sedatives as they relate to the management of mor-
bidly obese patients. None of the agents currently
available is ideal for every situation, though the reasons
for saying so differ from one agent or drug class to
another.
Benzodiazepines
The tide has been flowing against benzodiazepines as
first-line sedatives for several years [18]. Various reasons
may be adduced for this, including the possibility of a
causal relation between prolonged benzodiazepine expos-
ure and risk of delirium [18]. In any event, this general
trend extends to obese patients and may be accentuated
by the greater susceptibility of non-ventilated obese pa-
tients to compromised patency of the upper airways [19].
Effects on patency can be ameliorated by positioning ma-
noeuvres [20] but remain a consideration. In common
with other sedatives that act via γ-aminobutyric acid
(GABA)-ergic pathways, benzodiazepines can also ad-
versely affect respiratory drive and/or timing.
The availability of effective alternative agents now
makes a strong case to favour non-benzodiazepine seda-
tives in mechanically ventilated patients [18,21]. Obesity
does not detract from that case and may strengthen it.
Opioids
The propensity of opioids to cause or contribute to
upper airway obstruction and respiratory depression
makes a strong case against a reliance on these drugs in
any situation where a spontaneous voluntary effort of
breathing is required of the patient [22]. As a general
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longer-acting opioids in morbidly obese patients.
The lack of context-sensitive accumulation of remifen-
tanil makes this our preferred agent where a continuous
opioid infusion is required [23]. The short duration of
action of remifentanil allows it to be dosed on lean body
mass and this is an advantage. However, its rapid addict-
ive effect, strong hyperalgesia potential and other opioid
side effects place limits on remifentanil’s usefulness as a
sedative in the ICU. In non-intubated obese patients
with a large neck circumference, the risk of inducing or
worsening OSAS is a substantial concern.
Volatile anaesthetics
Stability of context-sensitive half-time and moderate ef-
fects on the respiratory system make volatile anaes-
thetics an attractive proposition for sedation in the
morbidly obese (Table 1) [16]. Individual studies have
provided positive comparisons with more conventional
sedatives [24]. However, substantial, controlled demon-
strations of their effectiveness and safety are absent and
volatile anaesthetics are not officially indicated forsedation. Reports on the effects of long-term isoflurane
delivered by the CE-approved AnaConDa® device
(Sedana Medical, Uppsala, Sweden) [25] illustrate some
of the haemodynamic pitfalls that may be encountered
with this unapproved use of volatile agents.
Concerns over possible nephrotoxicity with sevoflur-
ane [26,27] and more general anxieties about possible
adverse effects of chronic long-term exposure on pa-
tients and, more especially, on staff mean that experi-
ence is, in our opinion, unlikely to develop beyond the
local and anecdotal.
Propofol
Surveys of sedation practice on several continents indi-
cate a general tendency against very long-term use of
propofol [28-30]. This picture is confounded by observa-
tions linking propofol use to reductions in duration of
mechanical ventilation and overall ICU length of stay
(part of those effects may be due to displacement of
long-acting benzodiazepines) [29,31]. In general, how-
ever, trends in the use of this drug appear to be consist-
ent with the view that avoiding propofol infusion
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that for that purpose the duration of a continuous infu-
sion should not exceed 6 days.
Nevertheless, propofol is a well-defined and widely re-
lied upon sedative for short- and medium-term use
[32,33]. It has the value and attraction of being familiar
to trained anaesthetists even though we regard several of
its effects on the respiratory tract as suboptimal in the
context of managing obese patients (Table 1). Recently
reported experience with fospropofol is also encouraging
but in need of further development [34]. Fospropofol is
a water-soluble pro-drug and does not deliver the calorie
content of traditional propofol emulsion. This may be a
consideration.
Alpha-2 agonists
Alpha-2 agonists offer a range of theoretically positive
features in the sedation of morbidly obese patients
(Table 1) but suffer from a lack of relevant pharmacoki-
netic data and the lack of a critical mass of high-grade
clinical data. Nothing in the current dataset suggests
that these agents are suitable for achieving deep sedation
as monotherapy, though they may be combined with
other sedatives for procedural deep sedation. Dexmede-
tomidine has the attraction of not causing respiratory
depression or obstructive breathing during sedation
[35,36] and should deliver sufficient sympathetic blockade
to confer stable blood pressure and heart rate in many pa-
tients. Clonidine has an elimination half-time four times
that of dexmedetomidine and a correspondingly longer
duration of effect [37]: except in hard-to-specify circum-
stances where extended effect is desired, this is not likely
to be an advantage. The apparent dissociation between ef-
fects on bispectral index scores and subject rousability
suggest that clonidine is only suitable for light sedation.
However, in common with dexmedetomidine [38] and
other agents such as ketamine [39], it can be used as an
adjunct to reduce dosage requirements for analgo-
sedatives and is widely used in Germany, apparently for
that purpose [39].
Ketamine
Use of ketamine is substantially confined to paediatrics,
in part because of concerns about its tolerability profile
in adults [40]. Systematic analyses suggest that ketamine
may have a place in the analgo-sedation repertoire for
adults at least for its opioid-sparing effects [41,42] but,
owing to its stimulant action on the sympathetic nervous
system, it is difficult to regard it as a first-choice seda-
tive. Its use may also be associated with hallucinations
[40]. Combining of ketamine with benzodiazepines may
reduce the risk of hallucination though this is not a suf-
ficient reason to consider benzodiazepines when other-
wise they might not be.The risk of serious respiratory adverse events with
intravenous ketamine is low [43]. In the context of pro-
cedural sedation in the emergency department, use of
ketamine has been reported in one survey to be a pro-
tective factor for sedation-related airway events [44].
The drug has been assessed in broadly favourable terms
in that situation [45].
In general, the newer S-ketamine form has a better
tolerability profile than the previously available racemate.
Combinations such as ketofol (ketamine plus propofol)
and ketodex (ketamine plus dexmedetomidine) have
been reported to offer attractive features for procedural
sedation but much of that experience has been accrued
in paediatrics [46]. The few published investigations of
procedural sedation in adults are encouraging [47,48]
but the place of these combinations in the sedation of
obese adult ICU patients requires more investigation be-
fore conclusions may be reached and recommendations
issued. Matters in need of consideration include deter-
mination of the optimal dose ratios and structured ap-
praisal of adverse reactions [49].The future
Perhaps the most striking aspect of Table 1 is how much
current practice in this setting rests on opinion rather
than evidence [50].
The to-do list for the immediate future to rectify that
situation includes:
• acquiring robust pharmacokinetic data for the
alpha-2 agonists and for S-ketamine in obese
patients
• controlled comparisons of clonidine and
dexmedetomidine
• full characterization of the effects of
benzodiazepines on the upper airways and on
respiratory drive/muscle function in obese patients
• evaluation of multimodal sedative regimens.
Other themes we should like to see investigated in
morbidly obese ICU patients include:
• investigation of the short-term (in-hospital) and
longer-term (≥3 months) impact of sedation choices
on cognitive dysfunction [51-54]
• the interplay between sedation delivery and the
day–night cycle and sleep quality as it relates to
OSAS in non-intubated patients.Conclusions
We offer the following practical advice on the sedation
of morbidly obese patients vulnerable to OSAS and
obesity–hypoventilation syndrome.
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improved in the sitting (or ‘beach-chair’) position.
2. Endotracheal tubes should be the default airway choice
for morbidly obese patients in most sedation cases.
3. Avoid long-acting sedatives-there should be an
intention towards rapid emergence of the patient
from sedation after any procedure.
4. Avoid drugs with respiratory depressant effects that
reduce the breathing frequency and depth.
5. Avoid drugs that cause or exacerbate obstructive
breathing in non-intubated patients.
6. Monitor breathing and depth of sedation.
7. We support the view [55] that there are good reasons to
favour remifentanil and dexmedetomidine in particular
for the facilitation of awake fibre-optic intubation.
Abbreviations
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